Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
Top Page
GeoVax Labs
(NASDAQ:GOVX)
32Underperform
Positive Factors
Clinical Trials
GEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Financial Support
GeoVax Labs received a significant Project NextGen (PNG) award from BARDA worth $443M, indicating strong financial support for advancing their vaccine trials.
Market Position
GeoVax Labs is focused on near-term progress with its GEO-CM04S1 Phase 2 trials, which could position the company as a new vaccine player in 2025.
Negative Factors
Contract Termination
GeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
MRNA Vaccine Comparison
The DSMB did not recommend continuing the mRNA vaccine arm, which failed the study’s predetermined primary endpoint of the T cell-based immune response rate.
GeoVax Labs (GOVX) vs. S&P 500 (SPY)
Market Cap
$14.12M
Dividend YieldN/A
Average Volume (3M)660.61K
Price to Earnings (P/E)―
Beta (1Y)3.08
Revenue GrowthN/A
EPS Growth56.88%
CountryUS
Employees17
SectorHealthcare
Sector Strength69
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding13,839,478
10 Day Avg. Volume384,018
30 Day Avg. Volume660,611
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.03
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.99
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.70Price Target Upside1058.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
GeoVax Labs Business Overview & Revenue Model
Company DescriptionGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.
GeoVax Labs Financial Statement Overview
Summary
GeoVax Labs faces substantial financial hurdles, characterized by recurring losses and negative cash flows, despite having a debt-free balance sheet. The company's financial health is under pressure, with cash reserves being critical for sustaining operations.Income Statement
GeoVax Labs shows significant challenges in profitability, with consistently negative net income, EBIT, and EBITDA margins, indicating ongoing operational losses. The revenue growth for the TTM period is promising but comes from a low base, suggesting volatility in revenue generation.15
Very Negative
Balance Sheet
The company has a strong equity position relative to debt, with a zero debt-to-equity ratio. However, the return on equity is negative due to persistent losses, indicating inefficiency in generating shareholder value. The equity ratio is healthy, showing equity financing predominance.25
Negative
Cash Flow
GeoVax Labs exhibits negative free and operating cash flows, reflecting ongoing cash burn and potential liquidity challenges. The TTM period shows a sizable operating cash flow deficit relative to net income, suggesting operational cash flow inefficiencies.20
Very Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 81.00K | 385.00K | 1.82M | 1.18M | Gross Profit |
| -20.72M | 24.72K | -15.17M | -621.46K | -734.82K | EBIT |
| -26.74M | -14.03M | -18.75M | -2.82M | -2.37M | EBITDA |
| -26.67M | -13.97M | -18.53M | -2.79M | -2.36M | Net Income Common Stockholders |
| -25.97M | -14.01M | -18.53M | -2.94M | -2.38M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 6.45M | 27.61M | 11.42M | 9.88M | 283.34K | Total Assets |
| 9.28M | 31.35M | 11.80M | 10.39M | 468.88K | Total Debt |
| 0.00 | 0.00 | 0.00 | 198.06K | 39.74K | Net Debt |
| -6.45M | -27.61M | -11.42M | -9.69M | -243.60K | Total Liabilities |
| 3.52M | 4.75M | 7.43M | 825.00K | 2.04M | Stockholders Equity |
| 5.76M | 26.60M | 4.36M | 9.57M | -1.57M |
| Cash Flow | Free Cash Flow | |||
| -25.22M | -19.16M | -11.24M | -2.91M | -1.41M | Operating Cash Flow |
| -25.17M | -19.03M | -11.20M | -2.75M | -1.40M | Investing Cash Flow |
| -48.95K | -134.26K | -47.72K | -156.79K | -7.61K | Financing Cash Flow |
| 4.06M | 35.35M | 12.78M | 12.51M | 1.43M |
GeoVax Labs Technical Analysis
Negative
1.01
Price Trends
1.28
Negative
1.71
Negative
2.32
Negative
Market Momentum
-0.09
Negative
46.46
Neutral
65.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.28, and below the 200-day MA of 2.32, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 46.46 is Neutral, neither overbought nor oversold. The STOCH value of 65.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.35B | 3.41 | -40.83% | 2.89% | 18.11% | 2.60% | |
45 Neutral | $12.99M | 0.87 | -92.60% | ― | -70.05% | ― | |
44 Neutral | $13.94M | ― | -135.80% | ― | ― | 52.82% | |
44 Neutral | $9.72M | ― | -58.40% | ― | ― | 1.00% | |
43 Neutral | $15.78M | ― | -97.42% | ― | 234.31% | 79.88% | |
37 Underperform | $10.23M | ― | -114.83% | ― | ― | 81.71% | |
32 Underperform | $14.12M | ― | -462.31% | ― | ― | 56.88% |
* Healthcare Sector Average
Performance Comparison
GOVX
GeoVax Labs
1.01
-0.44
-30.34%
PHIO
Phio Pharmaceuticals
1.92
-4.93
-71.97%
MBRX
Moleculin Biotech
1.06
-4.00
-79.05%
ABVC
ABVC BioPharma
1.06
-0.07
-6.19%
ADXN
Addex Therapeutics
7.79
-0.32
-3.95%
SNSE
Sensei Biotherapeutics
0.40
-0.86
-68.25%
GeoVax Labs Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: -20.47%|
Next Earnings Date:May 01, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment. While there were significant achievements such as the BARDA award and advancements in vaccine development, financial challenges and delays in clinical trials were also highlighted.Q4-2024 Updates
Positive Updates
BARDA Project Next-Gen Award
GeoVax secured a $400 million award from BARDA for the development of the next-generation COVID-19 vaccine GEO-CM04S1, with the program underway and study sites confirmed.
Advancements in GEO-MVA Vaccine
Completion of cGMP product and quality release for GEO-MVA, GeoVax's vaccine candidate against Mpox and Smallpox, with sufficient product produced for clinical evaluation.
Increase in R&D Spending
Research and development expenses increased by 14% to $23.7 million in 2024, mainly due to the BARDA contract and manufacturing clinical trial materials.
Potential for Strategic Partnerships
GeoVax is focusing on establishing partnerships and collaborations for global development and commercialization of its vaccines.
Negative Updates
Net Loss for 2024
GeoVax reported a net loss of approximately $25 million for 2024, largely attributed to increased manufacturing activities and BARDA contract costs.
Decrease in Cash Balances
Cash balances decreased to $5.5 million by the end of 2024, reflecting a significant use of cash in operating activities.
Delays in Gedeptin Trial
The start of the next Gedeptin trial has been pushed to mid to late 2025 due to product manufacturing issues, causing a substantial delay.
Company Guidance
In the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call, the company provided guidance on several critical metrics and milestones for 2025. GeoVax announced its BARDA Project Next-Gen Award, valued at approximately $400 million, which supports the development of its next-generation COVID-19 vaccine, GEO-CM04S1. The company has confirmed all study sites and is advancing manufacturing processes to support the vaccine's clinical evaluation. They anticipate having the GEO-MVA vaccine, targeting Mpox and smallpox, ready for clinical evaluation in the latter half of 2025. For their Gedeptin cancer therapy, clinical operations are progressing with plans for a Phase II trial. Financially, GeoVax reported a net loss of $25 million for 2024, with revenues from the BARDA contract reaching $4 million. The company's cash balance stood at $5.5 million as of December 31, 2024, with strategic partnerships and financing activities planned to support ongoing development programs. The call also highlighted the company's commitment to addressing the unmet medical needs of immunocompromised populations with their COVID-19 vaccine and their strategic focus on establishing business partnerships for global development and distribution.GeoVax Labs Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025
On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.
To see Spark’s full report on GOVX stock, click here.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.